Publicacións en colaboración con investigadores/as de Universidad de Salamanca (19)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials

    Haematologica, Vol. 108, Núm. 4, pp. 969-980

2022

  1. Experimental Setup for Irradiation of Cell Cultures at L2A2

    Quantum Beam Science, Vol. 6, Núm. 1

  2. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Predictors of cardiovascular events and all-cause of death in patients with transfusion-dependent myelodysplastic syndrome

    British Journal of Haematology, Vol. 195, Núm. 4, pp. 536-541

2016

  1. Gene–gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patients

    Drug Metabolism and Pharmacokinetics, Vol. 31, Núm. 5, pp. 349-355

  2. High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma

    Annals of Hematology, Vol. 95, Núm. 2, pp. 253-262

2015

  1. Translational value of animal models of kidney failure

    European Journal of Pharmacology, Vol. 759, pp. 205-220

2014

  1. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers

    Breast Cancer Research and Treatment, Vol. 148, Núm. 2, pp. 415-421

  2. Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients

    Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704

2013

  1. Evaluation of Rare Variants in the New Fanconi Anemia Gene ERCC4 (FANCQ) as Familial Breast/Ovarian Cancer Susceptibility Alleles

    Human Mutation, Vol. 34, Núm. 12, pp. 1615-1618

  2. First symposium of ichthyosis experts

    Actas Dermo-Sifiliograficas

  3. Impact of pharmacogenetics on CNS side effects related to efavirenz

    Pharmacogenomics, Vol. 14, Núm. 10, pp. 1167-1178

  4. Response to lenalidomide in myelodysplastic syndromes with del(5q): Influence of cytogenetics and mutations

    British Journal of Haematology, Vol. 162, Núm. 1, pp. 74-86

2012

  1. Shorter telomere length is associated with increased: Ovarian cancer risk in both familial and sporadic cases

    Journal of Medical Genetics, Vol. 49, Núm. 5, pp. 341-344

2010

  1. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers

    Breast Cancer Research and Treatment, Vol. 119, Núm. 1, pp. 221-232

2008

  1. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain

    Clinical Cancer Research, Vol. 14, Núm. 9, pp. 2861-2869

2006

  1. Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer

    Clinical Chemistry, Vol. 52, Núm. 8, pp. 1480-1485

2003

  1. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: A high proportion of mutations unique to Spain and evidence of founder effects

    Human Mutation, Vol. 22, Núm. 4, pp. 301-312